This HTML5 document contains 69 embedded RDF statements represented using HTML+Microdata notation.

The embedded RDF content will be recognized by any processor of HTML5 Microdata.

Namespace Prefixes

PrefixIRI
n2http://linked.opendata.cz/resource/drugbank/drug/
dctermshttp://purl.org/dc/terms/
n8http://linked.opendata.cz/resource/AHFS/
n19http://linked.opendata.cz/resource/drugbank/company/
foafhttp://xmlns.com/foaf/0.1/
n16http://linked.opendata.cz/resource/drugbank/drug/DB00014/identifier/pharmgkb/
n24http://linked.opendata.cz/resource/drugbank/dosage/
n13http://linked.opendata.cz/resource/drugbank/drug/DB00014/identifier/wikipedia/
n6http://bio2rdf.org/drugbank:
admshttp://www.w3.org/ns/adms#
n21http://linked.opendata.cz/resource/drugbank/drug/DB00014/identifier/kegg-drug/
n22http://linked.opendata.cz/resource/drugbank/drug/DB00014/identifier/drugbank/
n15http://www.rxlist.com/cgi/generic/
n9http://linked.opendata.cz/resource/drugbank/patent/
n20http://wifo5-03.informatik.uni-mannheim.de/drugbank/resource/drugs/
rdfhttp://www.w3.org/1999/02/22-rdf-syntax-ns#
n14http://linked.opendata.cz/resource/drugbank/medicinal-product/
owlhttp://www.w3.org/2002/07/owl#
n3http://linked.opendata.cz/ontology/drugbank/
n23http://linked.opendata.cz/resource/drugbank/drug/DB00014/identifier/national-drug-code-directory/
n11http://www.drugs.com/cdi/
n4http://linked.opendata.cz/resource/drugbank/property/
xsdhhttp://www.w3.org/2001/XMLSchema#
n18http://linked.opendata.cz/resource/atc/
n7http://linked.opendata.cz/ontology/sukl/drug/

Statements

Subject Item
n2:DB00014
rdf:type
n3:Drug
n3:description
Goserelin is a synthetic hormone. In men, it stops the production of the hormone testosterone, which may stimulate the growth of cancer cells. In women, goserelin decreases the production of the hormone estradiol (which may stimulate the growth of cancer cells) to levels similar to a postmenopausal state. When the medication is stopped, hormone levels return to normal.
n3:dosage
n24:271B3F3C-363D-11E5-9242-09173F13E4C5 n24:271B3F3D-363D-11E5-9242-09173F13E4C5
n3:group
approved
n3:halfLife
4-5 hours
n3:indication
Used to treat hormone-sensitive cancers of the breast (in pre- and peri- menopausal women) and prostate, and some benign gynaecological disorders (endometriosis, uterine fibroids and endometrial thinning). In addition, goserelin is used in assisted reproduction and in the treatment of precocious puberty.
n3:manufacturer
n19:271B3F39-363D-11E5-9242-09173F13E4C5
owl:sameAs
n6:DB00014 n20:DB00014
dcterms:title
Goserelin
adms:identifier
n13:Goserelin n16:PA164747674 n21:D00573 n22:DB00014 n23:0310-0951-30
n3:mechanismOfAction
Goserelin is a synthetic decapeptide analogue of LHRH. Goserelin acts as a potent inhibitor of pituitary gonadotropin secretion when administered in the biodegradable formulation. The result is sustained suppression of LH and serum testosterone levels.
n3:packager
n19:271B3F38-363D-11E5-9242-09173F13E4C5
n3:patent
n9:7118552 n9:7500964
n3:routeOfElimination
Clearance of goserelin following subcutaneous administration of a radiolabeled solution of goserelin was very rapid and occurred via a combination of hepatic and urinary excretion. More than 90% of a subcutaneous radiolabeled solution formulation dose of goserelin was excreted in urine.
n3:synonym
Goserelin ICI-118630 Zoladex Goserelin acetate
n3:toxicity
No experience of overdosage from clinical trials.
n3:volumeOfDistribution
* 44.1 ± 13.6 L [subcutaneous administration of 250 mcg]
n7:hasAHFSCode
n8:92-00-00 n8:68-18-00
n3:proteinBinding
27.3%
n3:salt
n3:synthesisReference
Kripa S. Srivastava, Matthew R. Davis, "Solid Phase Peptide for the Production of Goserelin." U.S. Patent US20100311946, issued December 09, 2010.
foaf:page
n11:goserelin.html n15:goserel.htm
n3:IUPAC-Name
n4:271B3F42-363D-11E5-9242-09173F13E4C5
n3:InChI
n4:271B3F48-363D-11E5-9242-09173F13E4C5
n3:Molecular-Formula
n4:271B3F47-363D-11E5-9242-09173F13E4C5
n3:Molecular-Weight
n4:271B3F44-363D-11E5-9242-09173F13E4C5
n3:Monoisotopic-Weight
n4:271B3F45-363D-11E5-9242-09173F13E4C5
n3:SMILES
n4:271B3F46-363D-11E5-9242-09173F13E4C5
n3:Water-Solubility
n4:271B3F40-363D-11E5-9242-09173F13E4C5 n4:271B3F58-363D-11E5-9242-09173F13E4C5
n3:logP
n4:271B3F41-363D-11E5-9242-09173F13E4C5 n4:271B3F59-363D-11E5-9242-09173F13E4C5 n4:271B3F3E-363D-11E5-9242-09173F13E4C5
n3:logS
n4:271B3F3F-363D-11E5-9242-09173F13E4C5
n7:hasATCCode
n18:L02AE03
n3:H-Bond-Acceptor-Count
n4:271B3F4E-363D-11E5-9242-09173F13E4C5
n3:H-Bond-Donor-Count
n4:271B3F4F-363D-11E5-9242-09173F13E4C5
n3:InChIKey
n4:271B3F49-363D-11E5-9242-09173F13E4C5
n3:Polar-Surface-Area--PSA-
n4:271B3F4A-363D-11E5-9242-09173F13E4C5
n3:Polarizability
n4:271B3F4C-363D-11E5-9242-09173F13E4C5
n3:Refractivity
n4:271B3F4B-363D-11E5-9242-09173F13E4C5
n3:Rotatable-Bond-Count
n4:271B3F4D-363D-11E5-9242-09173F13E4C5
n3:absorption
Inactive orally, rapidly absorbed following subcutaneous administration.
n3:affectedOrganism
Humans and other mammals
n3:casRegistryNumber
65807-02-5
n3:clearance
* 121 +/- 42.4 mL/min [prostate cancer with 10.8 mg depot]
n3:containedIn
n14:271B3F3B-363D-11E5-9242-09173F13E4C5 n14:271B3F3A-363D-11E5-9242-09173F13E4C5
n3:Bioavailability
n4:271B3F54-363D-11E5-9242-09173F13E4C5
n3:Ghose-Filter
n4:271B3F56-363D-11E5-9242-09173F13E4C5
n3:MDDR-Like-Rule
n4:271B3F57-363D-11E5-9242-09173F13E4C5
n3:Number-of-Rings
n4:271B3F53-363D-11E5-9242-09173F13E4C5
n3:Physiological-Charge
n4:271B3F52-363D-11E5-9242-09173F13E4C5
n3:Rule-of-Five
n4:271B3F55-363D-11E5-9242-09173F13E4C5
n3:Traditional-IUPAC-Name
n4:271B3F43-363D-11E5-9242-09173F13E4C5
n3:pKa--strongest-acidic-
n4:271B3F50-363D-11E5-9242-09173F13E4C5
n3:pKa--strongest-basic-
n4:271B3F51-363D-11E5-9242-09173F13E4C5